General
Preferred name
VORICONAZOLE
Synonyms
UK-109496 ()
Voriconazole (Vfend) ()
VORICONAZOLE137234-62-9 ()
Voriconazole (UK-109496) ()
Vfend,UK-109496 ()
UK-109,496 ()
NSC-759888 ()
Vfend ()
Voriconazole-d3 ()
P&D ID
PD001669
CAS
137234-62-9
188416-29-7
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2002
Drug Status
approved
Drug indication
Invasive aspergillosis
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Triazole antifungal agent (Tocris Bioactive Compound Library)
Cell lines
0
Organisms
4
Compound Sets
24
AdooQ Bioactive Compound Library
A10978
Axon Medchem Screening Library
2044
Cayman Chemical Bioactives
15633
17803
ChEMBL Approved Drugs
CHEMBL638
ChEMBL Drugs
CHEMBL638
Drug Repurposing Hub
DrugBank
DB00582
DrugBank Approved Drugs
DB00582
DrugCentral
2846
DrugCentral Approved Drugs
2846
DrugMAP
DMAOL2S
DrugMAP Approved Drugs
DMAOL2S
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100716
MedChem Express Bioactive Compound Library
HY-76200
NCATS Inxight Approved Drugs
JFU09I87TR
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Voriconazole
TargetMol Bioactive Compound Library
T0120
The Spectrum Collection
Tocris Bioactive Compound Library
3760
External IDs
50
Properties
(calculated by RDKit )
Molecular Weight
349.12
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
2.18
TPSA
76.72
Fraction CSP3
0.25
Chiral centers
2.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
14-?? Demethylase
CYP2C19, CYP2C9, CYP3A4, CYP3A5, PTGS1
CYP51 inhibitor
Bacterial
Fungal
Fungal,P450 (e.g. CYP17)
Primary Target
Miscellaneous Compounds
Indication
esophageal candidiasis, aspergillosis, skin infections
MOA
Cytochrome P450 inhibitor
Therapeutic Class
Antifungal Agents
Source data